Brandon Aden1, Bohdan Nosyk2,3, Eve Wittenberg4, Bruce R Schackman1. 1. Department of Public Health, Weill Cornell Medical College, New York, NY (BA, BRS) 2. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada (BN) 3. Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada (BN) 4. Center for Health Decision Science, Harvard School of Public Health, Boston, MA (EW).
Abstract
PURPOSE: To assess the impact of illicit drug use and chronic hepatitis C virus (HCV) on health-related quality of life (HRQoL) in women with HIV or at risk for HIV infection. METHODS: Cross-sectional analysis of data from the Women's Interagency Health Study (WIHS) of women with HIV (n = 2508) and at high risk of HIV infection (n = 889) in the US. A Short-Form-6D (SF-6D) HRQoL measure derived from the Medical Outcomes Study-HIV (MOS-HIV) questionnaire, HIV infection status, CD4 cell count (a measure of immune status), antiretroviral treatment, current illicit drug use (heroin and/or cocaine), and HCV status were assessed at a recent study visit. We developed multivariate linear regression models adjusting for age, race/ethnicity, education, and testing for interactions. RESULTS: HIV-infected women with ≤200 CD4 cells/µL had lower mean HRQoL scores (0.69) than either HIV-infected women with >200 CD4 cells/µL (0.78) or HIV-uninfected women (0.80) (P < 0.01). In multivariate analysis, illicit drug use, chronic HCV, and low CD4 count were independently associated with lower HRQoL. There was a differential effect of HCV and illicit drug use for HIV-infected women depending on CD4 cell count: HIV-infected women with >200 CD4 cells/µL had a significantly greater reduction in HRQoL associated with illicit drug use (-0.063) and chronic HCV (-0.036) than women with ≤200 CD4 cells/µL (-0.017, -0.005 respectively). CONCLUSIONS: Poorly controlled HIV, illicit drug use, and chronic HCV are associated with lower HRQoL. Illicit drug use and chronic HCV have greater HRQoL impacts for HIV-infected women with well-controlled HIV versus those with poorly controlled HIV, which may affect clinical and policy priorities.
PURPOSE: To assess the impact of illicit drug use and chronic hepatitis C virus (HCV) on health-related quality of life (HRQoL) in women with HIV or at risk for HIV infection. METHODS: Cross-sectional analysis of data from the Women's Interagency Health Study (WIHS) of women with HIV (n = 2508) and at high risk of HIV infection (n = 889) in the US. A Short-Form-6D (SF-6D) HRQoL measure derived from the Medical Outcomes Study-HIV (MOS-HIV) questionnaire, HIV infection status, CD4 cell count (a measure of immune status), antiretroviral treatment, current illicit drug use (heroin and/or cocaine), and HCV status were assessed at a recent study visit. We developed multivariate linear regression models adjusting for age, race/ethnicity, education, and testing for interactions. RESULTS:HIV-infectedwomen with ≤200 CD4 cells/µL had lower mean HRQoL scores (0.69) than either HIV-infectedwomen with >200 CD4 cells/µL (0.78) or HIV-uninfectedwomen (0.80) (P < 0.01). In multivariate analysis, illicit drug use, chronic HCV, and low CD4 count were independently associated with lower HRQoL. There was a differential effect of HCV and illicit drug use for HIV-infectedwomen depending on CD4 cell count: HIV-infectedwomen with >200 CD4 cells/µL had a significantly greater reduction in HRQoL associated with illicit drug use (-0.063) and chronic HCV (-0.036) than women with ≤200 CD4 cells/µL (-0.017, -0.005 respectively). CONCLUSIONS: Poorly controlled HIV, illicit drug use, and chronic HCV are associated with lower HRQoL. Illicit drug use and chronic HCV have greater HRQoL impacts for HIV-infectedwomen with well-controlled HIV versus those with poorly controlled HIV, which may affect clinical and policy priorities.
Authors: M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis Journal: N Engl J Med Date: 1999-08-19 Impact factor: 91.245
Authors: Bohdan Nosyk; Huiyung Sun; Daphne P Guh; Eugenia Oviedo-Joekes; David C Marsh; Suzanne Brissette; Martin T Schechter; Aslam H Anis Journal: J Clin Epidemiol Date: 2010-03-17 Impact factor: 6.437
Authors: P Todd Korthuis; Mary Jo Tozzi; Vijay Nandi; David A Fiellin; Linda Weiss; James E Egan; Michael Botsko; Angela Acosta; Marc N Gourevitch; David Hersh; Jeffrey Hsu; Joshua Boverman; Frederick L Altice Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: Bruce R Schackman; Sue J Goldie; Kenneth A Freedberg; Elena Losina; John Brazier; Milton C Weinstein Journal: Med Decis Making Date: 2002 Jan-Feb Impact factor: 2.583
Authors: Dennis G Fryback; Nancy Cross Dunham; Mari Palta; Janel Hanmer; Jennifer Buechner; Dasha Cherepanov; Shani A Herrington; Ron D Hays; Robert M Kaplan; Theodore G Ganiats; David Feeny; Paul Kind Journal: Med Care Date: 2007-12 Impact factor: 2.983
Authors: Morgan M Philbin; Carrigan Parish; Margaret Pereyra; Daniel J Feaster; Mardge Cohen; Gina Wingood; Deborah Konkle-Parker; Adebola Adedimeji; Tracey E Wilson; Jennifer Cohen; Lakshmi Goparaju; Adaora A Adimora; Elizabeth T Golub; Lisa R Metsch Journal: J Health Commun Date: 2019-06-14
Authors: Eve Wittenberg; Jeremy W Bray; Brandon Aden; Achamyeleh Gebremariam; Bohdan Nosyk; Bruce R Schackman Journal: Addiction Date: 2015-12-17 Impact factor: 6.526
Authors: Bach Xuan Tran; Long Hoang Nguyen; Arto Ohinmaa; Rachel Marie Maher; Vuong Minh Nong; Carl A Latkin Journal: BMC Health Serv Res Date: 2015-01-22 Impact factor: 2.655
Authors: Jeffrey V Lazarus; Kelly Safreed-Harmon; Adeeba Kamarulzaman; Jane Anderson; Ricardo Baptista Leite; Georg Behrens; Linda-Gail Bekker; Sanjay Bhagani; Darren Brown; Graham Brown; Susan Buchbinder; Carlos Caceres; Pedro E Cahn; Patrizia Carrieri; Georgina Caswell; Graham S Cooke; Antonella d'Arminio Monforte; Nikos Dedes; Julia Del Amo; Richard Elliott; Wafaa M El-Sadr; María José Fuster-Ruiz de Apodaca; Giovanni Guaraldi; Tim Hallett; Richard Harding; Margaret Hellard; Shabbar Jaffar; Meaghan Kall; Marina Klein; Sharon R Lewin; Ken Mayer; Jose A Pérez-Molina; Doreen Moraa; Denise Naniche; Denis Nash; Teymur Noori; Anton Pozniak; Reena Rajasuriar; Peter Reiss; Nesrine Rizk; Jürgen Rockstroh; Diana Romero; Caroline Sabin; David Serwadda; Laura Waters Journal: Nat Commun Date: 2021-07-16 Impact factor: 14.919